Mode
Text Size
Log in / Sign up

FAPI PET/CT Shows Higher Sensitivity for Lymph Node Metastases in Breast Cancer

FAPI PET/CT Shows Higher Sensitivity for Lymph Node Metastases in Breast Cancer
Photo by Navy Medicine / Unsplash
Key Takeaway
Consider FAPI PET/CT as a potential adjunct for detecting regional lymph node metastases in breast cancer, but its lower specificity for primary lesions warrants caution.

This single-center post hoc retrospective analysis included 69 therapy-naïve women with suspected breast lesions (81 breast lesions, 797 regional lymph nodes, 94 distant metastases). The study compared the diagnostic accuracy of [18F]AlF-NOTA-FAPI-04 PET/CT with conventional imaging (ultrasonography, mammography, breast MRI, whole-body CT, and bone scan).

For primary breast lesions, conventional imaging showed a sensitivity of 93.75% and specificity of 100.00%, while visual PET/CT had a sensitivity of 98.44% and specificity of 70.59%. The AUC for conventional imaging was 0.970 versus 0.845 for visual PET/CT (P = 0.034), indicating significantly lower performance for PET/CT in this setting.

For regional lymph node metastases (LNM), visual PET/CT demonstrated significantly higher sensitivity (95.95% vs 73.99%) and specificity (97.60% vs 95.41%) compared to conventional imaging. Staging accuracy was also improved with PET/CT. Median follow-up was 4.5 months.

Safety and tolerability were not reported. Key limitations include the single-center design and retrospective analysis, which may introduce bias. The findings suggest that FAPI PET/CT may enhance detection of regional LNM, but prospective studies are needed before clinical adoption.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Conventional imaging has limitations in differentiating benign from malignant breast lesions and in staging breast cancer (BC). This study compared the diagnostic and staging performance of [18F]AlF-NOTA-FAPI-04 PET/CT with conventional imaging in suspected breast lesions. This single-center post hoc retrospective analysis included therapy-naïve participants with suspected breast lesions who underwent [18F]AlF-NOTA-FAPI-04 PET/CT between July 2023 and February 2025. All patients underwent ultrasonography, mammography, breast MRI, whole-body CT, and bone scan. Conventional imaging results were based on consensus visual interpretation integrating these modalities. PET/CT images were assessed visually and semi-quantitatively to assess the diagnostic accuracy. Lesions were confirmed by histopathology and follow-up (median, 4.5 months). Diagnostic performance for primary breast lesions, regional lymph nodes metastases (LNM), and distant metastases was evaluated on lesion-based, whereas visual scoring and staging (the AJCC eighth edition) comparisons were patient-based. Receiver operating characteristic/Delong and McNemar χ² analyses were performed using SPSS Statistics 29.0. A two-sided P  Sixty-nine women (median age, 50 years) with 81 breast lesions, 797 regional lymph nodes, and 94 distant metastases were included, and all 69 patients underwent ultrasonography, mammography, breast MRI, whole-body CT, and bone scan. For primary breast lesions, conventional imaging showed sensitivity and specificity of 93.75% and 100.00%, whereas visual PET/CT showed 98.44% and 70.59%. Although LBRbreast achieved the highest area under the curve (AUC), its AUC was not significantly different from that of conventional imaging (1.000 vs. 0.970, P = 0.078). In contrast, visual PET/CT showed a significantly lower AUC than conventional imaging (0.845 vs. 0.970, P = 0.034). For regional LNM detection, visual PET/CT achieved sensitivity and specificity of 95.95% and 97.60%, which were significantly higher than the corresponding values of conventional imaging (73.99% and 95.41%, all P  [18F]AlF-NOTA-FAPI-04 PET/CT outperforms conventional imaging in detecting regional LNM and improving pathological staging accuracy in BC.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.